Dr. Rogers on Data for Ibrutinib in Hairy Cell Leukemia
October 25th 2019
Kerry Rogers, MD, discusses the results from an ongoing phase II trial investigating ibrutinib in patients with relapsed/refractory hairy cell leukemia. Because this represents a very rare patient population, accrual began in 2013, and these data reflect on a small portion of the 39 patients enrolled.